在慢性炎症中适应蛋白的药理向
Shubhi Raizada1, Alexander G Obukhov2,3, Shreya Bharti1
1Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Indore, 453552, MP, India.
概括
准适应物分子为治疗慢性炎症疾病提供了一个有前途的战略. 治疗剂可以抑制关键信号通路,减少炎症和细胞因子的产生,但需要进一步的安全评估.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 炎症是对病原体,细胞损伤和毒素的关键免疫反应.
- 慢性炎症可能导致组织损伤和疾病,涉及NF-κB,MAPK和JAK-STAT等途径.
- 适应蛋白在炎症信号通路中至关重要,并与慢性炎症疾病有关.
研究的目的:
- 审查在慢性炎症反应中向适应分子的药理学药剂.
- 确定抑制炎症信号级联的治疗策略.
主要方法:
- 进行了全面的文献审查.
- 分析了针对适应分子的药理学剂的已发表的研究.
主要成果:
- 治疗策略包括小分子抑制剂,反感性寡核酸治疗和传统药物化合物.
- 这些药物有效地抑制炎症反应和促炎性细胞因子的产生.
- 主要机制涉及阻断炎症信号级联中的蛋白质-蛋白质相互作用.
结论:
- 向适应物分子为慢性炎症疾病提供了一种可行的治疗方法.
- 小分子,寡核酸和天然化合物显示出调节炎症的潜力.
- 广泛的临床前研究和风险评估对于确保这些治疗策略的安全性和有效性至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
126
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126
Intracellular Signaling Affects Focal Adhesions
2.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.6K
Amplifying Signals via Enzymatic Cascade
8.4K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124


